Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1757

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 8
Chunk 1757
---
000

    Convertible note payable

    800,000

    -

    Total current liabilities

    6,718,809

    2,038,272

    Deferred underwriting commissions

    2,070,000

    2,070,000

    Total Liabilities

    8,788,809

    4,108,272

    Commitments and Contingencies

    Common stock subject to possible redemption, 164,752 shares issued and outstanding  at redemption value of $11.21 per share and 3,467,954 shares issued and outstanding  at redemption value of $10.50 per share at December 31, 2024 and 2023, respectively

    1,847,643

    36,426,253

    Stockholders’ Deficit

    Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at December 31, 2024 and 2023

    -

    -

    Common stock; $0.0001 par value; 100,000,000 shares authorized; 2,155,000 issued and outstanding (excluding 164,752 shares subject to possible redemption) at December 31, 2024 and  2,155,000 issued and outstanding (excluding 3,467,954 shares subject to possible redemption) at December 31, 2023

    216

    216

    Additional paid-in capital

    -

    -

    Accumulated deficit

    (8,333,627
    )

    (3,907,008
    )
  
    Total Stockholders’ Deficit

    (8,333,411
    )

    (3,906,792
    )
  
    Total Liabilities and Stockholders’ Deficit
     
    $
    2,303,041

    $
    36,627,733

The accompanying notes are an integral part
of the consolidated financial statements.

F-3

OSR HOLDINGS, INC.

(f/k/a Bellevue Life
Sciences Acquisition Corp.)

CONSOLIDATED
STATEMENTS OF OPERATIONS

    For the Years Ended

    December 31,

    2024

    2023

    EXPENSES

    General and administrative expenses
     
    $
    3,524,549

    $
    1,830,700

    Loss